Project Grant R21HD115181
Award Date 8/1/24
Completion Date 7/31/26
Dollars Obligated $426K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55414, USA
Similar Awards
- Federal Grant Award Summary Sacyl Pharmaceuticals, Inc. received $799,998 in funding from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) to advance development of a novel, on-demand, non-hormonal male contraceptive toward Investigational New Drug (IND) enablement. The award, issued on September 22, 2025, with a completion date of September 21, 2026, supports a Phase I Small Business...
- This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is supporting research to understand tumorigenesis and identify therapeutic targets in CDK12-mutant prostate cancer. The $1,944,610 award, which began on April 1, 2025 and will run through March 31, 2028, was granted to the Sloan-Kettering Institute for Cancer Research, a leading nonprofit cancer research institution in New York. The research involves a...
- Capienda Biotech, LLC received a $329,272 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective August 1, 2025 through July 31, 2026. The company is developing a high-throughput kinetic measurement instrument that significantly advances small-molecule drug discovery capabilities. Building on a prior National Science Foundation Small Business Innovation Research (SBIR) Phase I prototype that enabled 128 simultaneous assays, this award...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program award provides $274,990 to Dencoda LLC to develop a novel DNA-based kinase assay platform. The key products to be delivered are: A highly sensitive, specific, and multiplexed kinase activity assay that can be used as a research tool to discover new therapeutic targets or as a clinical diagnostic test for diseases involving kinase dysregulation, such as cancers, diabetes, and Alzheimer's disease....
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $391,531 to Yale University to develop technology for directing phosphorylation of specific protein kinase substrates. The goal is to engineer a kinase mutant that can selectively phosphorylate a designer allele of one of its substrates, using knowledge of kinase phosphorylation site specificity. The researchers will establish the feasibility of this approach using the tumor...
- Federal Project Grant Award Summary The University of Texas at San Antonio (UTSA) received a $715,513 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop small molecule inhibitors targeting RBM46 as a novel male contraceptive. Awarded on February 11, 2026, with completion targeted for January 31, 2029, this research initiative addresses the NICHD's mission to...
- Federal Project Grant Award Summary Yale University received a $787,586 Project Grant from the National Institute of Child Health and Human Development under the Child Health and Human Development Extramural Research program (CFDA 93.865), effective February 1, 2026 through January 31, 2029. The research project focuses on engineering and targeting the sperm-specific calcium channel CatSper for development of non-steroidal male contraception. The funding supports a two-phase research...
- Federal Grant Award Summary The National Cancer Institute awarded a $3.11 million Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research, effective September 1, 2025, through August 31, 2029. This award supports fundamental research investigating TYK2 (tyrosine kinase 2) gene fusions in lymphoma, specifically examining the oncogenic mechanisms of NPM1::TYK2 fusion proteins discovered in ALK-negative anaplastic large cell...
- This Project Grant award of $125,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports fundamental research conducted by New York University School of Medicine from August 1, 2025, through July 31, 2027. The research investigates the role of Cyclin D1-CDK4/6 in protein homeostasis, specifically examining how cyclin D-dependent phosphorylation regulates the endoplasmic reticulum-associated degradation...
- Grant Award Summary Emory University received a $756,946 Project Grant award from the National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) effective August 1, 2025 through April 30, 2029. The project, titled "Delineating the Role of ALDH2 in Endometriosis," will conduct basic and translational research to understand the molecular mechanisms underlying endometriosis-associated pain and develop improved diagnostic and therapeutic...